(the "Company” or "Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the Company to ...

(the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the ...

“We are excited to bring this much needed product to Canada,” said Marc Edwards, President & CEO. “Congratulations to the Kane Biotech team for achieving this important milestone and continue to ...

(the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. We apologize, but this video has ...